Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

M. Filetti | R. Salazar | A. Maconi | F. Mazzoni | J. Tabernero | G. Gaidano | P. Queirolo | P. Pedrazzoli | A. Santoro | D. Ferrante | L. Rimassa | A. Marrari | A. Bertuzzi | C. Ficorella | D. Generali | S. Rossi | B. Vincenzi | G. Tonini | A. Patriarca | A. Prat | R. Berardi | A. Parisi | A. Cortellini | G. Porzio | D. Pinato | D. Ottaviani | Andrea Plaja | O. Mirallas | M. Lambertini | S. Bracarda | A. Aujayeb | B. Russell | M. van Hemelrijck | R. Mesía | R. Bertulli | R. Wuerstlein | L. Scotti | F. Zoratto | N. Diamantis | M. Bower | C. Tondini | A. Gennari | A. Sureda | A. Guida | R. Giusti | F. Biello | M. Saponara | R. Bruna | Margarita Viladot | I. Ruiz-Camps | V. Fusco | L. Cantini | S. Delfanti | M. Betti | C. Moss | S. Provenzano | F. Pommeret | G. Rizzo | T. Newsom-Davis | Alvin J X Lee | R. Sharkey | A. Dalla Pria | J. Aguilar-Company | Joan Brunet | U. Mukherjee | E. Seguí | J. Marco-Hernández | E. Roldán | L. Fox | C. Martínez-Vila | A. Loizidou | C. Maluquer | M. Libertini | E. Colomba | A. Sinclair | L. Chiudinelli | M. Perachino | F. D’Avanzo | A. Jackson | A. Baggi | S. Khalique | F. Paoloni | S. Bawany | T. Yu | V. Tovazzi | Lucy Rogers | N. Saoudi | M. Cucurull | Eleanor Apthorp | Cian Murphy | Katherine Belessiotis | M. Carmona-García | N. Saoudi-Gonzalez | Kris Doonga | Judith Swallow | Chris Chung | Meera Patel | G. Dettorre | Amani Chowdhury | A. Lee | C. Sng | Marianne Shawe-Taylor | H. D. Bain | C. Cruz | Simeon Eremiev | Roser Fort-Culillas | Raquel Liñan | F. Henze | M. Franchi | V. Fotia | R. Salazar | G. Hanbury | S. Townsend | David Garcia Illescas | Ramis Andaleeb | C. Martinez-Vila | Ana Sánchez de torre | R. Berardi | A. Santoro | Nadia Saoudi-Gonzalez | Maria Iglesias | Salvatore Grisanti | A. Zambelli | Sven Mahner | N. Harbeck | M. Lambertini | Aleix Prat | Paola Queirolo | M. Bower | J. Tabernero | E. Jones | Martine Piccart | Sabrina Rossi | Gianluca Gaidano | J. Brunet | Joanne S Evans | Eudald Felip | Roxana Reyes | Daniela Ferrante | Armando Santoro | M. Tucci | Simeón Eremiev | A. Sureda | Tamara Yu | Vittorio Fusco | David J. Joanne S. Judith Alessio Georgina Chris Meera G Pinato Evans Swallow Cortellini Hanbury Chu | Lee Cooper | Saorise Dolly | Ailsa Sita-Lumsde | M.C. Carmona Garcia | Robert Fort-Culillas | Marco Krengly | Federica Grosso | M. Piccart | E. Felip | Marianne Shawe-Taylor | P. Queirolo

[1]  C. Zheng,et al.  Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines , 2022, Journal of medical virology.

[2]  H. Jäck,et al.  The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.

[3]  A. Iafrate,et al.  Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer , 2021, Cancer Cell.

[4]  Y. Shyr,et al.  COVID-19 vaccination and breakthrough infections in patients with cancer , 2021, Annals of Oncology.

[5]  R. Salazar,et al.  Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. , 2021, JAMA oncology.

[6]  J. Lopez Bernal,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. , 2021, The New England journal of medicine.

[7]  M. Piccart,et al.  Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study , 2021, The Lancet Oncology.

[8]  M. Koopmans,et al.  mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial , 2021, The Lancet Oncology.

[9]  Robin L. Jones,et al.  Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study , 2021, Nature Cancer.

[10]  Robert L. Goldstone,et al.  Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. , 2021, Nature cancer.

[11]  T. Barrientos-Gutiérrez,et al.  Immunogenicity and Risk of SARS-CoV-2 Infection after COVID-19 Vaccination in Patients with Cancer: A Systematic Review and Meta-Analysis , 2021, European Journal of Cancer.

[12]  N. Kitchin,et al.  1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine , 2021, Annals of Oncology.

[13]  L. Tserel,et al.  Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study , 2021, The Lancet Regional Health - Europe.

[14]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[15]  D. Stuart,et al.  Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom , 2021, Nature Microbiology.

[16]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[17]  A. Addeo,et al.  Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer , 2021, Cancer Cell.

[18]  M. Ceppi,et al.  Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis , 2021, Critical Reviews in Oncology/Hematology.

[19]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[20]  R. Salazar,et al.  Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study , 2021, European Journal of Cancer.

[21]  R. Salazar,et al.  Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score , 2021, Journal for ImmunoTherapy of Cancer.

[22]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[23]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[24]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[25]  J. Mascola,et al.  Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.

[26]  C. Swanton,et al.  Consequences of COVID-19 for cancer care — a CRUK perspective , 2020, Nature Reviews Clinical Oncology.

[27]  R. Salazar,et al.  Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer , 2020, Cancer discovery.

[28]  J. Brunet,et al.  Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe , 2020, Cancers.

[29]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[30]  I. Siempos,et al.  Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data , 2020, JCO global oncology.

[31]  D. Kerr,et al.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.

[32]  S. Duffy,et al.  Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care , 2020, The Lancet Oncology.